BioTuesdays

Tag - DRRX

DURECT names Timothy Papp as CFO

DURECT (NASDAQ:DRRX) appointed Timothy Papp as chief financial officer to direct and oversee all financial and capital markets activities, including accounting, financial reporting, financial planning and analysis...

DURECT

Chardan starts DURECT at buy; PT $7

Chardan Capital Markets launched coverage of DURECT (NASDAQ:DRRX) with a “buy” rating and price target of $7. The stock closed at $1.76 on Oct. 29. “We expect that DURECT’s lead pipeline asset, DUR-928, will...

DURECT awaiting Pfizer meeting with FDA on Remoxy

DURECT (NASDAQ:DRRX) has a lot riding on a meeting in late March between its marketing partner, Pfizer, and the FDA to discuss resubmitting a new drug application for its lead pain drug, Remoxy, as a tamper-resistant...